CRDF vs NVX Comparison

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.